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Aims: The aim of this study is to explore whether administration timing affects glycaemic control by
lixisenatide once-daily in type 2 diabetes mellitus (T2DM).
Methods: A phase IIIb, open-label, 1:1 randomized, active-controlled, 24-week multicentre study of T2DM
patients inadequately controlled on metformin was conducted. Patients were administered lixisenatide
before breakfast or the main meal. The primary endpoint was change from baseline at week 24 in glycated
haemoglobin (HbA1c). Other endpoints: changes in body weight, fasting plasma glucose (FPG), 7-point self-
monitored plasma glucose (SMPG) and Diabetes Treatment Satisfaction Questionnaire status (DTSQs) score.
Adverse events (AEs) were monitored.
Results: Mean change in HbA1c from baseline at week 24 was−0.65% (−7.1 mmol/mol; main meal) and−
0.74% (−8.1 mmol/mol; breakfast). Mean changes in FPG, body weight and DTSQs score were comparable
between groups. Themean change in bodyweight (kg) was−2.60 (mainmeal) and−2.80 (breakfast group).
The 7-point SMPG proﬁles showed greatest reductions in postprandial glucose after the meal at which
lixisenatide was administered, with a residual effect seen on the subsequent meal. AE rates were similar
between groups, including gastrointestinal AEs.
Conclusions: Lixisenatide before the main meal was noninferior to lixisenatide before breakfast in patients
insufﬁciently controlled on metformin. Lixisenatide treatment allows ﬂexibility in administration timing.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Postprandial and fasting plasma glucose (PPG and FPG) contribute
to glycated haemoglobin (HbA1c) levels, and addressing both is
necessary to achieve sustained glycaemic control in patients with type
2 diabetes mellitus (T2DM) (American Diabetes Association, 2013;
Garber et al., 2013).cturing and/or consultancy for
b, GSK, Merck, Novartis, Novo
inhibitors or GLP-1 receptor
eaker and consulting fees from
eneca, Eli Lilly, Boehringer
nson.
ences, Lund University,
220758; fax: +46 462220757.
Inc. This is an open access article uPostbreakfast glucose excursions are a universal phenomenon that
occur early in T2DM evolution (Monnier et al., 2002). Morning
hyperglycaemia is thought to occur due to a deﬁcit in insulin secretion
in patients with T2DM, acting in concert with circadian variations in
hepatic glucose output, which peaks in the early morning due to
overnight fasting (Bavenholm, Pigon, Ostenson, & Efendic, 2001;
Boden, Chen, & Urbain, 1996). As such, effective management of
postbreakfast hyperglycaemia is an important treatment target in
patients with T2DM (Monnier et al., 2002). Many patients experience
substantial PPG excursions after meals other than breakfast, and blood
glucose changes have been shown to be driven by carbohydrate intake
in patients who respond to treatment (Franc et al., 2010). For
example, when moderate- and high-carbohydrate lunches were
compared in metformin-treated patients with T2DM, the high-
carbohydrate lunch signiﬁcantly increased postprandial peak glucose
levels and prolonged the time taken for glucose to return to
preprandial levels (Powers, Cuddihy, Wesley, & Morgan, 2010). It isnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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than breakfast, which could be achieved with prandial medications
with ﬂexible administration timing.
Lixisenatide is a once-daily prandial glucagon-like peptide-1 receptor
agonist (GLP-1 RA) for the treatment of T2DM. Lixisenatide mimics the
effects of endogenous GLP-1, increasing insulin secretion and suppress-
ing glucagon release (Christensen, Knop, Vilsboll, & Holst, 2011).
Lixisenatide also delays gastric emptying, which prolongs glucose
absorption, improving control of PPG excursions (Lorenz et al., 2013).
Lixisenatide is a modiﬁed form of exendin-4 (a partial GLP-1 homolog),
with a C-terminus of six lysine residues, allowing it to withstand
degradation by dipeptidyl peptidase 4, and prolonging activity.
With the exception of the GetGoal-M study (Ahrén, Leguizamo,
Miossec, Saubadu, & Aronson, 2013), which assessed morning and
evening lixisenatide dosing, studies in the phase III GetGoal program
investigated the efﬁcacy and safety of lixisenatide administered
before breakfast. Timings of administration and dose were kept
consistent across the majority of GetGoal studies to reduce potential
confounding factors, which established the efﬁcacy of a set lixisena-
tide regimen administered as a monotherapy or in combination with
other agents in patients poorly controlled on oral antidiabetic drugs
(OADs) or basal insulin (Ahrén et al., 2013; Bolli et al., 2013; Fonseca
et al., 2012; Pinget et al., 2013; Riddle, Aronson, et al., 2013; Riddle,
Forst, et al., 2013; Rosenstock et al., 2013; Seino, Min, Niemoeller, &
Takami, 2012). This study is the ﬁrst to assess the efﬁcacy of
lixisenatide dosing prior to the main meal.
2. Materials and methods
2.1. Study design
This was a 24-week, phase IIIb, open-label, 1:1 randomized, active-
controlled, two-arm, parallel-group, multicentre study of patients
with T2DM inadequately controlled on metformin (Supplementary
Fig. 1). This study aimed to demonstrate the noninferiority of
lixisenatide 20 μg once-daily administered within the hour before
the main meal of the day (breakfast, lunch or dinner) compared with
within the hour before breakfast in terms of HbA1c change at week 24.
Themainmeal of the daywas deﬁned at visit 2 based on each patient's
answer to the question: “On most days, at which meal do you eat
the largest amount of food?” The main meal of the day was also
independently determined by a dietician. Patients were stratiﬁed by
randomization strata of the main meal of the day, as determined by
the patients, and by screening of HbA1c (b8% [b64 mmol/mol] or≥8%
[≥64 mmol/mol]). The study was conducted across 10 countries
(Canada, the Czech Republic, France, Germany, Poland, Romania, the
Russian Federation, Spain, Ukraine, the USA) between February 2012
and May 2013 (see Appendix 1 for participating investigators).
Lixisenatide 10 μg once-daily was administered for the ﬁrst
2 weeks of the study and then continued at 20 μg once-daily until
study end. A reduction to 10 μg per day could bemade if 20 μg per day
was not tolerated, but an attempted increase to 20 μg per day had to
be made within 4 weeks; if the attempted increase failed, the patient
was maintained on 10 μg per day throughout the study. All regimens
were administered subcutaneously using the Opticlik® (Sanoﬁ, Paris,
France) self-injector device.
In the main meal group and breakfast group, lixisenatide was
administered within the hour before the main meal and the hour
before breakfast, respectively.
2.2. Inclusion criteria
All patients in this study met the following criteria at screening:
T2DM for ≥1 year; treated with metformin at a stable dose of
≥1.5 g/day for ≥3 months; and HbA1c ≥7% (53 mmol/mol) and
≤10% (86 mmol/mol).2.3. Study populations
The safety population was the randomized and treated population,
deﬁned as all randomized patients who were exposed to at least one
dose of the lixisenatide, regardless of length of treatment. Efﬁcacy
analyses were based on themodiﬁed intent-to-treat (mITT) population
corresponding with all randomized patients who received at least one
dose of lixisenatide and had a baseline assessment and at least one
postbaseline assessment of any primary or secondary efﬁcacy endpoint.
2.4. Endpoints
The primary endpoint of this phase IIIb study was change in HbA1c
from baseline to week 24 with lixisenatide administered within the
hour before breakfast or the main meal of the day. Secondary
endpoints included: the proportion of HbA1c responders (HbA1c b7%
[b53 mmol/mol] or ≤6.5% [≤48 mmol/mol] at week 24); change in
body weight, FPG and 7-point self-monitored plasma glucose (SMPG)
from baseline at week 24. Change in treatment satisfaction from
baseline to week 24 was also assessed by the Diabetes Treatment
Satisfaction Questionnaire status (DTSQs) score in participating
countries and where validated. Total score was calculated as sums
of items 1 and 4–8 (Supplementary Table 1), which measured
treatment satisfaction. Each item was scored on a 7-point scale,
ranging from 0 (very dissatisﬁed) to 6 (very satisﬁed). Items 2 and 3
were treated individually (Bradley, 1994). Safety endpoints were
adverse events (AEs), serious AEs, symptomatic hypoglycaemia, vital
signs and safety laboratory values, which were monitored throughout
the study. Symptomatic hypoglycaemia was deﬁned as an event with
clinical symptoms that were considered to be a result of a
hypoglycaemic episode with plasma glucose b60 mg/dl (3.3 mmol/l)
or, if no plasma glucose measurement was available, was associated
with prompt recovery after oral carbohydrates, intravenous glucose or
glucagon administration. Severe hypoglycaemia was deﬁned as
clinical symptoms that the patient could not manage alone due to
acute neurological impairment and required assistance from another
person, and plasma glucose b36 mg/dl (2.0 mmol/l) or, if a plasma
glucose level was not available, the event was associated with a
prompt recovery after carbohydrates, intravenous glucose or glucagon
administration. Treatment-emergent AEs (TEAEs)were deﬁned as AEs
that developed orworsened during open-label treatment and for up to
3 days after the last administration of lixisenatide.
This study also examined the following composite endpoints at
week 24: HbA1c levels b7% and no conﬁrmed (plasma glucose
b60 mg/dl [3.3 mmol/l]) symptomatic hypoglycaemia; HbA1c levels
b7% and no weight gain; HbA1c levels b7%, no symptomatic
hypoglycaemia and no weight gain; HbA1c levels b7% and 2-hour
PPG b140 mg/dl after the main meal or breakfast.
2.5. Statistical methods
The statistical test for change in HbA1c from baseline at week 24
was one-sided, with alpha levels of 0.025 using a noninferiority
margin of 0.4% HbA1c. The primary endpoint was analyzed using an
analysis of covariance (ANCOVA) model, with treatment (lixisenatide
administered within the hour before the main meal of the day or
within the hour before breakfast), randomization strata of main meal
of the day (breakfast, lunch or dinner), randomization strata of
screening HbA1c (b8% [b64 mmol/mol] or ≥8% [≥64 mmol/mol])
and country as ﬁxed effects, and using the baseline HbA1c value as a
covariate. Baseline values were deﬁned as the last available value
taken before the ﬁrst dose of lixisenatide was administered. The
difference between treatment groups and two-sided 95% conﬁdence
intervals (CIs) was estimated within the framework of the ANCOVA
model. Noninferiority was demonstrated if the upper boundary of the
two-sided 95% CIs was ≤0.4%.
Table 1
Demographics and clinical characteristics at screening or at baseline—randomized population.
Parameter Main meal
(n = 225)
Breakfast
(n = 226)
Age, mean years (SD) 56.3 (10.6) 57.5 (9.7)
Male/female, % 44.9/55.1 42.9/57.1
Race, n (%)
Caucasian 211 (93.8) 211 (93.4)
Black 4 (1.8) 8 (3.5)
Asian 10 (4.4) 7 (3.1)
Other 0 0
Duration of diabetes, mean years (SD) 6.7 (4.9) 7.8 (5.6)
BMI, mean kg/m2 (SD) 33.5 (4.5) 32.8 (4.6)
Patients in each BMI category (%)
b30 kg/m2 22.7 26.5
≥30 kg/m2 77.3 73.5
Body weight, mean kg (SD) 95.0 (16.1) 92.9 (17.2)
FPG, mean mmol/l (SD)* 9.2 (2.0) 9.3 (2.0)
HbA1c, mean % (SD) 7.85 (0.76) 7.93 (0.78)
Daily metformin dose, mean mg (SD) 2040.7 (390.0) 2091.2 (1255.3)
Duration of metformin treatment, mean years (SD) 4.8 (4.1) 5.6 (4.6)
FPG, n = 225 for both treatment groups.
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin;
mITT, modiﬁed intent-to-treat; SD, standard deviation.
Table 2
Efﬁcacy outcomes at week 24—mITT population.
Outcomes Main meal
(n = 224)
Breakfast
(n = 226)
LS mean difference
(s.e.) for main meal
versus breakfast
[95% CI]
n 218 222
LS mean change in HbA1c,
% (mmol/mol); [s.e.]
−0.65 (−7.1)
[0.074]
−0.74 (−8.1)
[0.074]
0.09 (1.0) [0.079]
[−0.067, 0.242]
Responders in each category, n (%)
≤6.5% (48 mmol/mol) 49 (22.5) 57 (25.7) −3.1 [−11.03,4.75]
b7.0% (53 mmol/mol) 95 (43.6) 95 (42.8) 1.0 [−7.91, 9.91]
n 202 200
LS mean change in average
7-point SMPG, mmol/l (s.e.)
−0.80 (0.145) −1.10 (0.145) 0.30 (0.154)
[−0.008 to 0.598]
n 220 224
LS mean change in body
weight, kg (s.e.)
−2.60 (0.320) −2.80 (0.319) 0.21 (0.339)
[−0.46, 0.87]
n 220 222
LS mean change in FPG,
nmol/l (s.e.)
−0.35 (0.192) −0.57 (0.193) 0.22 (0.200)
[−0.176, 0.611]
n 224 226
LS mean change in DTSQs
score (s.e.)
3.01 (0.546) 3.54 (0.529) −0.53 (0.549)
[−1.609, 0.550]
CI, conﬁdence interval; DTSQs, Diabetes Treatment Satisfaction Questionnaire status
FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; LS, least squares; mITT
modiﬁed intent-to-treat; s.e., standard error; SMPG, self-monitored plasma glucose.
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ANCOVA model. All categorical efﬁcacy parameters were analyzed
using the Cochran–Mantel–Haenszel method stratiﬁed by the ran-
domization strata of mainmeal of the day and HbA1c at screening. The
difference between groups in terms of the number of patients with
symptomatic hypoglycaemia was analyzed based on the two-sided
Fisher's exact test. Safety analyses were descriptive and were
performed using the safety population.
3. Results
A total of 451 patients were randomized: 225 patients were
randomized to the main meal group and 226 patients were
randomized to the breakfast group. One hundred and eighty-nine
(84.0%) and 202 (89.4%) patients from the main meal and breakfast
groups, respectively, completed the study, with the most common
reason for discontinuation in both groups cited as the occurrence of
AEs (4.4 and 4.9% of patients in the main meal and breakfast groups,
respectively). All patients were included in the safety population. One
patient was exposed to lixisenatide for 1 day but did not have any
postbaseline efﬁcacy measures and was not included in the mITT
population; otherwise, the mITT population and safety populations
were identical (Supplementary Fig. 2).
Patient demographics and baseline characteristics were compara-
ble across groups, with the exception of patients in the breakfast
group having a slightly longer duration of diabetes and metformin
treatment at baseline compared with the main meal group (Table 1).
A similar proportion of patients and dieticians considered the
same meal of the day to be the ‘main’ meal, with the patient
determining the main meal by answering the question: “On most
days, at whichmeal do you eat the largest amount of food?”, while the
dietician assessed calorie intake and meal composition. In total, 8.2,
53.0 and 38.8% classiﬁed breakfast, lunch or dinner as the main meal,
compared with 10.2, 53.5 and 36.3% classiﬁed by dieticians,
respectively. In the mITT population, patients and dieticians deﬁned
the samemeal as the main meal in 86.2 and 81.9% of cases in the main
meal and breakfast groups, respectively.
3.1. Change in HbA1c
Lixisenatide administration within the hour before the main meal
(breakfast, lunch or dinner) was noninferior in terms of change in;
,HbA1c to lixisenatide administration within the hour before breakfast
in patients with T2DM inadequately controlled on metformin. The
least squares (LS) mean change (standard error [s.e.]) in HbA1c from
baseline at week 24 was −0.65% (0.074%) or −7.1 mmol/mol
(0.8 mmol/mol) for the main meal group and −0.74% (0.074%) or
−8.1 mmol/mol (0.8 mmol/mol) for the breakfast group (LS mean
difference for the main meal versus breakfast groups: 0.09%
[1.0 mmol/mol; 95% CI: −0.07%, 0.24%]; p = 0.2664) (Table 2;
Fig. 1A). Based on the prespeciﬁed primary analysis, noninferiority
of the main meal group compared with the breakfast group was
demonstrated, as the upper bound of the two-sided 95% CI of the LS
mean difference was less than the predeﬁned noninferiority margin
of 0.4%.
3.2. Proportion of HbA1c responders
Comparable proportions of patients in the two groups were HbA1c
responders. The proportions of patients in the main meal group who
achieved HbA1c ≤6.5% (48 mmol/mol) or b7% (53 mmol/mol) were
22.5 and 43.6%, respectively, compared with 25.7 and 42.8%,
respectively, in the breakfast group (Table 2).
3.3. FPG and body weight
Comparable reductions in FPG (Table 2) and body weight (Table 2;
Fig. 1B) were seen in the two groups. The LSmean (s.e.) change in FPG
was−0.35 (0.192) and−0.57 (0.193) mmol/l for the main meal and
breakfast groups, respectively. The LS mean (s.e.) change in body
weight (kg) from baseline to week 24 was−2.60 (0.320) for the main
meal group and −2.80 (0.319) for the breakfast group.
3.4. SMPG proﬁles
From the SMPG proﬁles, the average 7-point SMPG was estimated
for the main meal group and the breakfast group. The LS mean change
(s.e.) from baseline in average 7-point SMPG at week 24 was −0.80
(0.145) mmol/l for the main meal group and −1.10 (0.145) mmol/l
for the breakfast group (Table 2). Fig. 1C shows the SMPG proﬁles at
baseline and week 24 for the breakfast group (as randomized) and
Fig. 1. A—mean HbA1c (%) by visit—mITT population. The plot included measurements
obtained up to 14 days after the last injection of the investigational medicinal product.
LOCF, last observation carried forward; SE, standard error. B—mean change in body
weight (kg) from baseline by visit—mITT population. The plot included measurements
obtained up to 3 days after the last injection of the investigational medicinal product.
LOCF, last observation carried forward; SE, standard error. C—7-Point SMPG proﬁles
(mmol/l) at each time point at baseline and Week 24—mITT population. The plot
included measurements obtained up to the date of the last injection of the
investigational medicinal product. *Includes patients from the main meal group with
breakfast, lunch or dinner as themainmeal of the day as deﬁned by the patient at visit 2.
LOCF, last observation carried forward; SE, standard error.
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All main meal subgroups, and the breakfast group, showed lower pre-
breakfast glucose values (fasting values) at week 24 than at baseline.
Within themainmeal group, differences were observed depending on
the time of lixisenatide administration. In the main meal subgroups, a
large reduction in glucose was observed after the meal at which
lixisenatide was administered, with a less pronounced effect observed
at the subsequent meal in the breakfast and lunch subgroups. It was
also found that bedtime glucose was reduced to a larger degree in the
main meal group when lixisenatide was given before dinner
compared with before breakfast or lunch (mean change from baseline
at week 24 glucose at bedtime was−0.03,−0.93 and−1.04 mmol/l
for the breakfast, lunch and dinner groups, respectively). The mean
change at bedtime from baseline at week 24 in patients randomized to
breakfast was −1.04 mmol/l.
3.5. Composite endpoints
The percentage of patients reaching HbA1c b7% with no
symptomatic hypoglycaemia at week 24 was 40.4% for the main
meal group and 41.0% for the breakfast group (response rate [r.r.]
difference = −0.5% [95% CI −9.39 to 8.44%]). A comparable
proportion of patients in both treatment groups reached HbA1c b7%
with no weight gain at week 24 (40.8 and 38.6% in the main meal and
breakfast group, respectively; r.r. difference = 2.4% [95% CI−6.39 to
11.24%]) and HbA1c b7% with no weight gain at week 24 and no
hypoglycaemia during the treatment period (38.1 and 37.2% in the
main meal and breakfast group, respectively; r.r. difference = 1.0%
[95% CI−7.82 to 9.77%]). The percentage of patients achieving HbA1c
b7% and 2-hour PPG b140 mg/dl at week 24 was 28.9% for the main
meal group and 27.6% for the breakfast group (r.r. difference = 1.5%
[95% CI −6.62 to 9.64%]).
3.6. DTSQs score
The LS mean (s.e.) change in DTSQs was 3.01 (0.546) and 3.54
(0.529) for the main meal and breakfast group, respectively; LS mean
difference of −0.53 (95% CI −1.609 to 0.550).
3.7. Adverse events
Themean duration of study treatmentwas 157.6 and 161.1 days in
the main meal and breakfast groups, respectively. At the end of
treatment, 95.6 and 96.5% of patients in the main meal and breakfast
groups were receiving lixisenatide 20 μg once-daily, indicating that
the maintenance dose was well-tolerated in most patients, irrespec-
tive of treatment group.
There were slightly fewer TEAEs in the main meal group than in
the breakfast group. Percentages of patients reporting serious TEAEs
and TEAEs leading to treatment discontinuation were similarly low
(Supplementary Table 2).
A total of 55/225 (24.4%) and 58/226 (25.7%) patients in the main
meal and breakfast groups, respectively, experienced gastrointestinal
(GI) TEAEs. Consistent with the mechanism of action of lixisenatide as
a GLP-1 RA, nausea was the most frequently reported AE in both
groups, with an incidence of approximately 15% (Table 2; Supple-
mentary data). Four (1.8%) patients from the main meal group and
three (1.3%) from the breakfast group discontinued treatment due to
nausea and/or vomiting.
Two patients reported allergic reactions that were positively
adjudicated as allergic reactions by an independent allergic reaction
assessment committee (ARAC): urticaria (1 [0.4%] patient in the main
meal group) and asthma (1 [0.4%] patient in the breakfast group).
Neither was adjudicated as possibly related to lixisenatide treatment
by the ARAC.Four (1.8%) patients in themainmeal group and three (1.3%) in the
breakfast group had a TEAE of increased lipase reported on the speciﬁc
AE form for increase lipase and/or amylase N2 times the upper limit of
normal. No cases of pancreatitis were reported during the study.
Nopatients in themainmeal group and two patients in the breakfast
group had a TEAE of increased calcitonin ≥20 pg/ml reported on the
speciﬁc AE form for increased calcitonin: both patients had calcitonin
levels N20 pg/ml on day 1 of the study, and the highest calcitonin value
for these patients during the study was 27 and 43 pg/ml.
The incidence of symptomatic hypoglycaemia (according toprotocol
deﬁnition) was low in both groups: 5.8% (13/225) in the main meal
group and 2.2% (5/226) in the breakfast group (p = 0.0581). The
annualized rate of symptomatic hypoglycaemia per patientwas 0.24 for
themainmeal group and 0.059 for the breakfast group. No patient from
either group experienced severe symptomatic hypoglycaemia.
The timing of symptomatic hypoglycaemic events varied between
the breakfast group and themainmeal subgroups (Table 3). Six events
were observed in patients randomized to the breakfast group. In the
Fig. 1 (continued).
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subgroup, 12 were observed in the lunch subgroup and 12 in the
dinner subgroup.Table 3
Symptomatic hypoglycaemia during the on-treatment period by hour of the day.
Time of day Main meal (n = 225)a Breakfast
(n = 226)b
Breakfast
(n = 19)
Lunch
(n = 119)
Dinner
(n = 87)
Total number of events 0 12 12 6
23:00 to b06:00 0 1 0 1
06:00 to b10:00 0 1 0 0
10:00 to b14:00 0 2 0 1
14:00 to b18:00 0 5 0 2
18:00 to b23:00 0 3 12 2
Missing 0 0 0 0
a Patients from the main meal group with breakfast, lunch or dinner as main meal o
the day as deﬁned by the patient at visit 2.
b Patients who were randomized to the breakfast group.4. Discussion
This phase IIIb study indicated that reductions in HbA1c by
lixisenatide were similar, regardless of whether it was administered
before breakfast or before the main meal of the day. These ﬁndings
offer patients ﬂexibility in the timing of administration, allowing users
to manage their PPG excursions according to their eating habits and
personal needs. Similar rates (approximately 40%) of patients in the
main meal and breakfast groups reached the HbA1c target of 7%
(53 mmol/mol). Body weight loss, change in average SMPG proﬁles,
FPG reductions, change in DTSQs score and composite endpoints were
also comparable between the groups. Lixisenatide was well-tolerated,
and the occurrence of symptomatic hypoglycaemia and GI TEAEs was
as expected for GLP-1 RAs in combination with stable metformin.
The current study used a simple approach to deﬁne the main meal
of the day, with the patient making the determination at the second
study visit. Interestingly, that determination was found to be
consistent with an objective dietician review of each patient's typical
meal intake pattern, indicating that assistance from a dietician would
not have signiﬁcantly affected outcomes. Assessing the differences
and similarities between patients and dieticians in the determination
of the main meal is a unique characteristic of this study.This studywas performed acrossmultiple countries. Overall results
demonstrate that dieticians and patients deﬁne the main meal of the
day in the sameway, regardless of possible differences in howdifferent
nationalities deﬁne their main meal. In the future, further analysis
could be performed taking into consideration cultural differences.
Flexibility in the timing of medications with predominantly prandial
activity may be desirable to optimize patient adherence by allowing the
freedom to administer therapywith either breakfast or themainmeal. This
ﬂexibility may be of beneﬁt to healthcare providers. It was recently
demonstrated that treatment with GLP-1 RAs is associated with good
patient satisfaction rates (Davies&Speight, 2012). Indeed,ﬂexibility indosef
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ability. For example, inﬂexibility in the timing of insulin injections has been
cited as a reason for nonadherence (Peyrot, Barnett, Meneghini, &
Schumm-Draeger, 2012). Furthermore, a recent systematic review of 17
studies found that ﬂexible regimens improved insulin therapy adherence
(Davies et al., 2013). DTSQs data from this study found that lixisenatide
improved treatment satisfaction independentof timingofadministration in
patients with T2DM insufﬁciently controlled onmetformin, with improve-
ment appearing to be driven partly by lowering of HbA1c and weight.
The7-point SMPGproﬁles for patients treatedbeforebreakfastor the
main meal of the day demonstrated that lixisenatide had the strongest
effect in reducing PPG excursions after the meal at which it was
administered. However, when lixisenatide was given before breakfast,
PPGwas also reduced after lunch and dinner, andwhen lixisenatidewas
given before lunch, PPG was also reduced after dinner, although the
effects on PPG excursions at the subsequentmealwere less pronounced.
Taken together, these data indicate that lixisenatide had a longer
pharmacodynamic effect than expected from its short half-life, and
covers meals other than those at which it is administered. This
conclusion is supported by a recent study from Lorenz and colleagues,
which evaluated the effects of lixisenatide on PPG (area under the curve
and peak levels) after a standardized meal at breakfast, lunch and
dinner, on gastric emptying at breakfast, and the relationship between
the effects on PPG and gastric emptying. The results indicated that
lixisenatide 20 μg administered once daily in the morning reduces PPG
levels throughout the day, and that the reduction in PPG, at least after
breakfast, is attributable to a delay in gastric emptying (Lorenz et al.,
2013). The effect at bedtime was largest when lixisenatide was
administered at dinner; this effect probably explains why there was
nodifference in reduction inHbA1c, regardless ofwhen lixisenatidewas
given, even though the dinner dose covered only one meal, whereas
breakfast and lunch dosing covered more than one meal.
Alternative timing of lixisenatide administration (dinner and
breakfast administration) was also investigated in the GetGoal-M
study. GetGoal-M was not designed to compare the efﬁcacy of
lixisenatide administered in the morning versus in the evening;
instead, each regimen was compared with placebo. As such, although
the improved glycaemia versus placebo was similar in the two groups,
direct comparisons between morning and evening lixisenatide dosing
could not be drawn (Ahrén et al., 2013). However, the effects
observed in GetGoal-M were similar to those in this study, with an
HbA1c decrease of−0.9% (9.8 mmol/mol) in the morning group and
−0.8% (8.7 mmol/mol) in the evening group, and 43 and 40.6% of the
patients reaching HbA1c target b7% (53 mmol/mol) in the morning
and evening groups, respectively (Ahrén et al., 2013).
One limitation of this studywas that therewere no study centres in
Asia. In the future it would be useful to look at the effect of lixisenatide
administered before the main meal versus breakfast in Asian patients
to assess whether dietary differences and the preponderance of
sulphonylurea use affect the control of PPG excursions at different
times of the day. Future studies could also assess themechanism of the
ﬂexibility of administration timing and investigate whether this
ﬂexibility translates into increased patient compliance.
In patients with T2DM insufﬁciently controlled on metformin,
prandial lixisenatide once-daily administered before breakfast or the
main meal was equally well-tolerated and resulted in comparable
reductions in HbA1c. This ﬁnding allows patients to select the most
convenient administration timing without compromising glycaemic
efﬁcacy, beneﬁcial effects on weight loss or tolerability of lixisenatide
in order to facilitate the achievement of glycaemic targets.
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